Stockscreener 앱 받기
103.92
0.16%
0.17
시간 외 거래:
103.92
전일 마감가:
$103.75
열려 있는:
$103.78
하루 거래량:
1.88M
Relative Volume:
0.79
시가총액:
$19.84B
수익:
$3.08B
순이익/손실:
$-986.58M
주가수익비율:
-19.54
EPS:
-5.3172
순현금흐름:
$292.08M
1주 성능:
+0.63%
1개월 성능:
+0.61%
6개월 성능:
+94.90%
1년 성능:
+127.40%
1일 변동 폭
$103.72
$103.96
1주일 범위
$103.45
$104.00
52주 변동 폭
$38.81
$104.00
이그젝트 사이 Stock (EXAS) Company Profile
명칭
Exact Sciences Corp
전화
608-284-5700
주소
5505 ENDEAVOR LANE, MADISON, WI
Compare EXAS vs TMO, DHR, IDXX, A, WAT
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
EXAS
Exact Sciences Corp
|
103.92 | 19.80B | 3.08B | -986.58M | 292.08M | -5.3172 |
|
TMO
Thermo Fisher Scientific Inc
|
470.21 | 172.63B | 44.56B | 6.72B | 6.29B | 17.74 |
|
DHR
Danaher Corp
|
190.11 | 135.42B | 24.57B | 3.60B | 5.26B | 5.051 |
|
IDXX
Idexx Laboratories Inc
|
579.85 | 45.95B | 4.30B | 1.06B | 1.04B | 13.08 |
|
A
Agilent Technologies Inc
|
111.75 | 31.51B | 7.07B | 1.29B | 993.00M | 4.5355 |
|
WAT
Waters Corp
|
299.57 | 28.94B | 3.17B | 642.63M | 516.49M | 10.77 |
이그젝트 사이 Stock (EXAS) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2026-01-20 | 다운그레이드 | Mizuho | Outperform → Neutral |
| 2026-01-05 | 다운그레이드 | Evercore ISI | Outperform → In-line |
| 2025-04-10 | 개시 | Mizuho | Outperform |
| 2025-03-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2025-01-23 | 개시 | Barclays | Overweight |
| 2024-08-28 | 개시 | Wells Fargo | Overweight |
| 2024-06-27 | 개시 | Scotiabank | Sector Outperform |
| 2024-06-03 | 재개 | Jefferies | Buy |
| 2024-01-02 | 업그레이드 | The Benchmark Company | Hold → Buy |
| 2023-12-14 | 개시 | Guggenheim | Buy |
| 2023-12-13 | 개시 | Wolfe Research | Outperform |
| 2023-10-10 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2023-09-28 | 개시 | Bernstein | Outperform |
| 2023-08-02 | 다운그레이드 | The Benchmark Company | Buy → Hold |
| 2023-05-10 | 업그레이드 | Craig Hallum | Hold → Buy |
| 2023-05-05 | 개시 | UBS | Neutral |
| 2023-03-09 | 업그레이드 | Citigroup | Neutral → Buy |
| 2023-02-10 | 다운그레이드 | Credit Suisse | Outperform → Neutral |
| 2023-01-18 | 다운그레이드 | Raymond James | Outperform → Mkt Perform |
| 2022-10-19 | 다운그레이드 | Craig Hallum | Buy → Hold |
| 2022-08-25 | 개시 | Credit Suisse | Outperform |
| 2022-06-03 | 개시 | Piper Sandler | Neutral |
| 2021-11-03 | 다운그레이드 | Raymond James | Strong Buy → Outperform |
| 2021-07-29 | 재확인 | BTIG Research | Buy |
| 2021-07-29 | 재확인 | Canaccord Genuity | Buy |
| 2021-07-29 | 재확인 | Oppenheimer | Outperform |
| 2021-07-29 | 재확인 | Stifel | Buy |
| 2021-06-15 | 개시 | Raymond James | Strong Buy |
| 2021-06-03 | 개시 | Goldman | Buy |
| 2021-05-25 | 개시 | Wells Fargo | Equal Weight |
| 2021-01-28 | 개시 | Truist | Buy |
| 2020-10-29 | 다운그레이드 | UBS | Buy → Neutral |
| 2020-10-28 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2020-10-08 | 재개 | BTIG Research | Buy |
| 2020-04-02 | 개시 | Evercore ISI | Outperform |
| 2020-01-10 | 재개 | BTIG Research | Buy |
| 2020-01-07 | 개시 | Citigroup | Buy |
| 2019-12-13 | 개시 | Dougherty & Company | Buy |
| 2019-11-15 | 개시 | Stifel | Buy |
| 2019-10-17 | 재확인 | BofA/Merrill | Buy |
| 2019-10-01 | 재개 | Craig Hallum | Buy |
| 2019-09-26 | 개시 | Oppenheimer | Outperform |
| 2019-02-26 | 업그레이드 | Goldman | Neutral → Buy |
| 2018-10-09 | 개시 | UBS | Buy |
| 2018-09-05 | 재개 | The Benchmark Company | Hold |
| 2018-08-13 | 재확인 | Canaccord Genuity | Buy |
| 2018-04-03 | 업그레이드 | BTIG Research | Neutral → Buy |
| 2018-01-29 | 개시 | Goldman | Neutral |
| 2018-01-08 | 재확인 | The Benchmark Company | Buy |
| 2017-11-13 | 다운그레이드 | Robert W. Baird | Outperform → Neutral |
| 2017-11-01 | 다운그레이드 | BTIG Research | Buy → Neutral |
모두보기
이그젝트 사이 주식(EXAS)의 최신 뉴스
1 Magnificent Dividend Stock Down 22% That's a Screaming Buy Right Now - The Motley Fool
Exact Sciences Develops Home Colon Cancer Test Kit [da9403] - fathomjournal.org
Health care again among the state’s biggest M&A deals of the past yearBizTimes - BizTimes - Milwaukee Business News
EXACT Sciences Corp. Hits New 52-Week High at $104.00 - Markets Mojo
Exact Sciences to Present New Molecular Residual Disease and Multi-Cancer Early Detection Data at AACR 2026 - The Joplin Globe
EXACT Sciences Corp. Hits New 52-Week High at $103.92 - Markets Mojo
Wisconsin InnoExact Sciences' multi-cancer blood test | Curate acquired - The Business Journals
Exact Sciences (EXAS) merger with Abbott moving forward after shareholder approval - MSN
Jain Global LLC Purchases Shares of 481,607 Exact Sciences Corporation $EXAS - MarketBeat
EXAS Stock Price, Quote & Chart | EXACT SCIENCES CORP (NASDAQ:EXAS) - ChartMill
Exact Sciences Corp Stock (ISIN: US30063P1057) Attracts Major Investors Amid Cancer Screening Moment - AD HOC NEWS
Exact Sciences Corporation $EXAS Shares Purchased by EFG Asset Management Americas Corp. - MarketBeat
Privia Health Screening Program Increases Colorectal Cancer Screening Rates - MyChesCo
Mackenzie Financial Corp Has $150.11 Million Stake in Exact Sciences Corporation $EXAS - MarketBeat
Analysts Set Exact Sciences Corporation (NASDAQ:EXAS) Target Price at $92.13 - National Today
EXACT Sciences Corp. Hits New 52-Week High of $103.75 - Markets Mojo
Schroder Investment Management Boosts Stake in Exact Sciences - National Today
Capital World Investors Reduces Stake in Exact Sciences - National Today
Exact Sciences Case Study Links Higher Screening Rates With Undervalued Shares - Yahoo Finance
Exact Sciences stock hits 52-week high at 103.68 USD By Investing.com - Investing.com Canada
Exact Sciences stock hits 52-week high at 103.68 USD - Investing.com India
Exact Sciences EHR Outreach Program Highlights Cologuard Growth And Valuation Debate - simplywall.st
Evercore ISI Group downgrades Exact Sciences (EXAS) - MSN
Exact Sciences Stock Falls Premarket Despite Wall Street Calling For A Triple-Digit Abbott Takeover - Stocktwits
Pentwater Capital Management LP's Exact Sciences Corp(EXAS) Holding History - GuruFocus
A Look At Exact Sciences (EXAS) Valuation After Strong 1 Year Shareholder Returns - simplywall.st
CSLLY or EXAS: Which Is the Better Value Stock Right Now? - Yahoo! Finance Canada
Exact Sciences Named Gallup Exceptional Workplace Award Winner for Third Consecutive Year - BioSpace
EXACT SCIENCES CORP (NASDAQ:EXAS) Shows Strong Technical and Fundamental Momentum - ChartMill
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration - BioSpace
Exact Sciences Stock: Is The Post-Earnings Slide A Buying Setup for 2026? - AD HOC NEWS
Exact Sciences (NASDAQ: EXAS) EVP exercises 3,900 options, 1,913 shares withheld - Stock Titan
Exact Sciences (EXAS) CEO reports RSU vesting and tax-withheld share dispositions - Stock Titan
KeyCare, Inc. announced that it has received $27.4 million in funding from a group of investors - marketscreener.com
Is Exact Sciences (EXAS) Pricing Reflect Long Term Cancer Screening Growth Potential - Yahoo Finance
Marking National Colorectal Cancer Awareness Month, Privia Health Program Achieves 84% Colorectal Cancer Screening Rate Through Industry Collaboration – Company AnnouncementFT.com - Financial Times
Exact Sciences Corporation $EXAS Shares Sold by Fox Run Management L.L.C. - MarketBeat
EXAS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
[Form 4] EXACT SCIENCES CORP Insider Trading Activity - Stock Titan
EXACT Sciences (EXAS) HR EVP awarded 23,224 RSUs in new grant - Stock Titan
Exact Sciences (EXAS) grants SVP Herriott 20,321 restricted stock units - Stock Titan
EXACT Sciences (EXAS) CEO receives major RSU grant and tax-share withholding - Stock Titan
Exact Sciences (EXAS) awards 28,063 restricted stock units to EVP Baranick - Stock Titan
Exact Sciences (NASDAQ: EXAS) EVP receives 38,707 restricted stock units - Stock Titan
Exact Sciences (EXAS) Merger with Abbott Moving Forward After Shareholder Approval - Insider Monkey
December 18th Options Now Available For EXACT Sciences (EXAS) - Nasdaq
Market Outlook: Is Exact Sciences Corporation showing insider buyingJuly 2025 Selloffs & Free Weekly Chart Analysis and Trade Guides - baoquankhu1.vn
Abbott Labs Increases Dividends for 54 Years, Acquires Exact Sciences - Intellectia AI
Abbott offers $20B in notes to finance Exact Sciences acquisition - MassDevice
Abbott Laboratories (ABT) sells $20B of notes to finance Exact Sciences acquisition - Stock Titan
Exact Sciences stock hits 52-week high at $103.55 By Investing.com - Investing.com India
이그젝트 사이 (EXAS) 재무 분석
매출
순이익
현금흐름
주당 순 이익
0.55%
2.50%
자본화:
|
볼륨(24시간):